incobotulinumtoxinA clinical trials
Also written NT 201.
A product of Botulinum toxin type A; its studies count on that page too.
How each study uses incobotulinumtoxinA is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the incobotulinumtoxinA studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Dec 1991 · BOTOX COSMETIC · BLA 103000 (FDA, Drugs@FDA; as botulinum toxin type A)
- European Union
- 27 Sept 2019 · Nuceiva · EMEA/H/C/004587 (EMA; as botulinum toxin type A)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 4
Merz Pharmaceuticals GmbH (8) · Merz North America, Inc. (4) · Merz Aesthetics GmbH (3) · Buddhist Tzu Chi General Hospital (1) · University of Malaya (1) · University of Miami (1) · Sir Run Run Shaw Hospital (1)
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Botulinum toxin type A source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test incobotulinumtoxinA.
- Sep 2027Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)Phase 2 · University of Miami
Studies
Open first, then newest update. How each study uses incobotulinumtoxinA is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)RecruitingPhase 2University of MiamiNCT06293300Written as BoNT AHow we know
- A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the ArmCompletedPhase 2Merz Pharmaceuticals GmbHNCT04766723Written as NT 201How we know
- A Study of NT 201 Doses in the Treatment of Platysma ProminenceCompletedPhase 2Merz Aesthetics GmbHNCT05773053Written as NT 201How we know
- A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)Active, not recruitingPhase 3Merz Aesthetics GmbHNCT07210463Written as NT 201How we know
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain InjuryActive, not recruitingPhase 3Merz Pharmaceuticals GmbHNCT03992404Written as NT 201How we know
- A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United StatesActive, not recruitingPhase 3Merz North America, Inc.NCT07122193Written as NT 201How we know
- A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the FaceCompletedPhase 1Merz North America, Inc.NCT05784363Written as NT 201How we know
- Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial LinesCompletedPhase 3Merz North America, Inc.NCT04622254Written as NT 201How we know
- Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial LinesCompletedPhase 3Merz North America, Inc.NCT04594213Written as NT 201How we know
- Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown LinesCompletedPhase 2Merz Aesthetics GmbHNCT03806933Written as NT 201How we know
- Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual DisabilityCompletedPhase 3Merz Pharmaceuticals GmbHNCT02270736Written as NT 201How we know
- Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder SyndromeCompletedPhase 2Buddhist Tzu Chi General HospitalNCT01657409Written as BoNT-A (10 injection)How we know
- The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke AdultsStatus unknownPhase 4Sir Run Run Shaw HospitalNCT02505802Written as BoNT-A injectionHow we know
- Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological DiseasesCompletedPhase 2/3University of MalayaNCT02425176Written as Botulinum toxin A (BoNT-A) 50UHow we know
- Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing DisordersWithdrawnPhase 2Merz Pharmaceuticals GmbHNCT00773591Written as NT 201, a Botulinum neurotoxin type A, free of complexing proteinsHow we know
- Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical DystoniaCompletedPhase 4Merz Pharmaceuticals GmbHNCT00541905Written as NT 201How we know
- Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown LinesCompletedPhase 3Merz Pharmaceuticals GmbHNCT00694148Written as NT 201How we know
- NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown LinesCompletedPhase 3Merz Pharmaceuticals GmbHNCT00777803Written as NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))How we know
- Blepharospasm Short IntervalTerminatedPhase 2Merz Pharmaceuticals GmbHNCT00507637Written as NT 201How we know
Given beside what is tested · 1 — incobotulinumtoxinA is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 21, 2026.
Results posted1
- A Study of NT 201 Doses in the Treatment of Platysma ProminenceNov 10, 2026NCT05773053
Codes
What other systems call incobotulinumtoxinA · ClinicalTrials.gg INT005533
- MeSH (NLM) C545476incobotulinumtoxinAOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545476 | incobotulinumtoxinA | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.